Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366777 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL23534464 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL599741 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL16401330 | 0.88 | CYP2C19 (0.49) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL16401654 | 0.88 | CYP2C19 (0.49) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL16401332 | 0.88 | CYP2C19 (0.49) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL20680343 | 0.86 | CYP1A2 (0.56) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL19357333 | 0.86 | CYP1A2 (0.56) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL14322640 | 0.85 | CYP1A2 (0.58) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL600897 | 0.85 | CYP1A2 (0.58) | CYP2C19CYP1A2GMNNUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399220-A1 | ANTIVIRAL STRUCTURALLY-STAPLED SARS-COV-2 PEPTIDE- CHOLESTEROL CONJUGATES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-118202043-A | Peptides with multivalent action | 英图库尔公司 | 2024-06-14 | — | — | CN | claimed |
| EP-3359180-B1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC (US) | 2024-05-15 | — | — | EP | claimed |
| US-20240124529-A1 | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | claimed |
| US-11952432-B2 | Cell-permeable stapled peptide modules for cellular delivery | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-09 | — | — | US | claimed |
| US-11945846-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | claimed |
| US-20240016943-A1 | SYNTHETIC DNA BINDING DOMAINS AND USES THEREOF | THE UNIVERSITY OF CHICAGO (US) | 2024-01-18 | — | — | US | claimed |
| US-11865181-B2 | Peptidic materials that traffic efficiently to the cell cytosol and nucleus | YALE UNIVERSITY | 2024-01-09 | — | — | US | claimed |
| CN-117304295-A | Stabilized BCL9 peptides for the treatment of aberrant Wnt signaling | 北京佳诚生物医药科技开发有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230405134-A1 | NOVEL PROTAC CHIMERIC COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING, AMELIORATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION | POSTECH Research and Business Development Foundation (KR) | 2023-12-21 | — | — | US | claimed |
| US-8940864-B2 | Stabilized therapeutic small helical antiviral peptides | NEW YORK BLOOD CENTER, INC. (US) | 2015-01-27 | — | — | US | claimed |
| US-8937154-B2 | Stabilized therapeutic small helical antiviral peptides | NEW YORK BLOOD CENTER, INC. (US) | 2015-01-20 | — | — | US | claimed |
| US-8933019-B2 | Antiviral cell-penetrating peptides | NEW YORK BLOOD CENTER, INC. (US) | 2015-01-13 | — | — | US | claimed |
| WO-2014072916-A1 | MIMETIC PEPTIDES | LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2014-05-15 | — | — | WO | claimed |
| US-20130059776-A1 | Antiviral Cell-Penetrating Peptides | NEW YORK BLOOD CENTER | 2013-03-07 | — | — | US | claimed |
| US-8324153-B2 | Antiviral cell-penetrating peptides | NEW YORK BLOOD CENTER, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20120165249-A1 | Stabilized Therapeutic Small Helical Antiviral Peptides | NEW YORK BLOOD CENTER, INC. | 2012-06-28 | — | — | US | claimed |
| EP-2283033-A1 | ANTIVIRAL CELL PENETRATING PEPTIDES | New York Blood Center (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090281041-A1 | ANTIVIRAL CELL-PENETRATING PEPTIDES | NEW YORK BLOOD CENTER | 2009-11-12 | — | — | US | claimed |
| WO-2009137532-A1 | ANTIVIRAL CELL PENETRATING PEPTIDES | NEW YORK BLOOD CENTER (US) | 2009-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124529-A1 | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | ACE2, SARS1, ACE | CYP2C19 4011/4885CYP1A2 4648/4885GMNN 2187/4885 |
| US-20240016943-A1 | SYNTHETIC DNA BINDING DOMAINS AND USES THEREOF | CBFB, CNBP, BPTF | CYP2C19 4837/4885CYP1A2 4719/4885GMNN 983/4885 |
| US-20230405134-A1 | NOVEL PROTAC CHIMERIC COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING, AMELIORATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION | SRC, PSME1, PSMB11 | CYP2C19 4204/4885CYP1A2 4336/4885GMNN 3909/4885 |
| US-20130059776-A1 | Antiviral Cell-Penetrating Peptides | ZC3HAV1, MAVS, HAVCR2 | CYP2C19 4477/4885CYP1A2 4845/4885GMNN 1535/4885 |
| US-11945846-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | VIP, SPPL2B, HM13 | CYP2C19 4707/4885CYP1A2 4876/4885GMNN 2115/4885 |
| US-11952432-B2 | Cell-permeable stapled peptide modules for cellular delivery | TAP1, TAP2, HM13 | CYP2C19 4852/4885CYP1A2 4885/4885GMNN 1079/4885 |
| US-20120165249-A1 | Stabilized Therapeutic Small Helical Antiviral Peptides | ZC3HAV1, VIP, ZC3HAV1L | CYP2C19 4716/4885CYP1A2 4867/4885GMNN 1121/4885 |
| US-20090281041-A1 | ANTIVIRAL CELL-PENETRATING PEPTIDES | ZC3HAV1, MAVS, HAVCR2 | CYP2C19 4477/4885CYP1A2 4845/4885GMNN 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.